Anchor Investment Management LLC Has $724,000 Holdings in Baxter International Inc. $BAX

Anchor Investment Management LLC grew its stake in Baxter International Inc. (NYSE:BAX) by 3.4% during the 1st quarter, HoldingsChannel.com reports. The firm owned 21,164 shares of the medical instruments supplier’s stock after buying an additional 701 shares during the period. Anchor Investment Management LLC’s holdings in Baxter International were worth $724,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Horizon Investments LLC grew its position in Baxter International by 5.0% in the 1st quarter. Horizon Investments LLC now owns 7,438 shares of the medical instruments supplier’s stock worth $255,000 after purchasing an additional 351 shares during the last quarter. Rothschild Investment LLC grew its position in Baxter International by 3.4% in the 1st quarter. Rothschild Investment LLC now owns 14,479 shares of the medical instruments supplier’s stock worth $496,000 after purchasing an additional 481 shares during the last quarter. Archer Investment Corp grew its position in Baxter International by 20.5% in the 1st quarter. Archer Investment Corp now owns 2,935 shares of the medical instruments supplier’s stock worth $100,000 after purchasing an additional 500 shares during the last quarter. Home Federal Bank of Tennessee grew its position in Baxter International by 2.5% in the 1st quarter. Home Federal Bank of Tennessee now owns 22,600 shares of the medical instruments supplier’s stock worth $774,000 after purchasing an additional 550 shares during the last quarter. Finally, Private Trust Co. NA grew its position in Baxter International by 17.3% in the 1st quarter. Private Trust Co. NA now owns 3,822 shares of the medical instruments supplier’s stock worth $131,000 after purchasing an additional 565 shares during the last quarter. 90.19% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have issued reports on BAX shares. Wells Fargo & Company decreased their price target on shares of Baxter International from $33.00 to $24.00 and set an “equal weight” rating on the stock in a research report on Friday, August 1st. The Goldman Sachs Group downgraded shares of Baxter International from a “buy” rating to a “neutral” rating and set a $25.00 price objective for the company. in a report on Friday, August 1st. Citigroup reduced their price objective on shares of Baxter International from $34.00 to $32.00 and set a “neutral” rating for the company in a report on Wednesday, July 9th. Morgan Stanley reduced their price objective on shares of Baxter International from $28.00 to $27.00 and set an “underweight” rating for the company in a report on Tuesday, July 15th. Finally, UBS Group reduced their price objective on shares of Baxter International from $35.00 to $24.00 and set a “neutral” rating for the company in a report on Monday, August 4th. Three research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Baxter International presently has a consensus rating of “Hold” and an average price target of $30.11.

Baxter International Trading Down 1.8%

Shares of BAX stock opened at $24.01 on Thursday. Baxter International Inc. has a 12-month low of $21.33 and a 12-month high of $40.49. The company has a market capitalization of $12.33 billion, a P/E ratio of -80.02, a P/E/G ratio of 0.80 and a beta of 0.61. The firm has a 50-day moving average price of $25.87 and a 200 day moving average price of $29.55. The company has a quick ratio of 1.49, a current ratio of 2.30 and a debt-to-equity ratio of 1.30.

Baxter International (NYSE:BAX) last announced its quarterly earnings results on Thursday, July 31st. The medical instruments supplier reported $0.59 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.60 by ($0.01). Baxter International had a negative net margin of 1.42% and a positive return on equity of 16.96%. The firm had revenue of $2.81 billion for the quarter, compared to the consensus estimate of $2.82 billion. During the same period in the prior year, the business earned $0.68 earnings per share. The company’s revenue for the quarter was up 4.3% on a year-over-year basis. Baxter International has set its Q3 2025 guidance at 0.580-0.620 EPS. FY 2025 guidance at 2.420-2.520 EPS. Research analysts forecast that Baxter International Inc. will post 2.48 earnings per share for the current fiscal year.

Baxter International Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 1st. Shareholders of record on Friday, August 29th will be paid a $0.17 dividend. The ex-dividend date of this dividend is Friday, August 29th. This represents a $0.68 dividend on an annualized basis and a dividend yield of 2.8%. Baxter International’s payout ratio is currently -226.67%.

Baxter International Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.